Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Having examined the options trading patterns of Eli Lilly, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance With a ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary ...

Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026. Despite macroeconomic headwinds ...

Eli Lilly stock rises more than 11% as weight loss pill orforglipron shows promising trial results, raising hopes for a ...

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the stock.Despite broader market uncertainties, the company ...